Active substance
Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients).
Heplisav B is indicated for the active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The use of Heplisav B should be in accordance with official recommendations. It can be expected that hepatitis D will also be prevented by immunisation with Heplisav B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
PreHevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults. It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. The use of PreHevbri should be in accordance with official recommendations.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ENGERIX-B | 02487020 | 10 MCG / 0.5 ML | SUSPENSION · INTRAMUSCULAR | GLAXOSMITHKLINE INC |
| ENGERIX-B | 02487039 | 20 MCG / 1 ML | SUSPENSION · INTRAMUSCULAR | GLAXOSMITHKLINE INC |
| RECOMBIVAX HB | 02245977 | 40 MCG / ML | SUSPENSION · INTRAMUSCULAR | MERCK CANADA INC |
| RECOMBIVAX HB | 02561476 | 5 MCG / 0.5 ML | SOLUTION · INTRAMUSCULAR | MERCK CANADA INC |
| RECOMBIVAX HB | 02561484 | 10 MCG / 1 ML | SOLUTION · INTRAMUSCULAR | MERCK CANADA INC |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.